Saravanan Jebarani

983 total citations
30 papers, 624 citations indexed

About

Saravanan Jebarani is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Saravanan Jebarani has authored 30 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Genetics and 6 papers in Surgery. Recurrent topics in Saravanan Jebarani's work include Diabetes Treatment and Management (12 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Diabetes Management and Research (7 papers). Saravanan Jebarani is often cited by papers focused on Diabetes Treatment and Management (12 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Diabetes Management and Research (7 papers). Saravanan Jebarani collaborates with scholars based in India, United Kingdom and United States. Saravanan Jebarani's co-authors include Viswanathan Mohan, Ranjit Mohan Anjana, Rajendra Pradeepa, Ranjit Unnikrishnan, Ewan R. Pearson, Muthuswamy Balasubramanyam, Moneeza K. Siddiqui, Anand Thakarakkattil Narayanan Nair, Coimbatore Subramanian Shanthirani and Bibin Yesodha Subramanian and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Diabetologia.

In The Last Decade

Saravanan Jebarani

28 papers receiving 608 citations

Peers

Countries citing papers authored by Saravanan Jebarani

Since Specialization

Citations

This map shows the geographic impact of Saravanan Jebarani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saravanan Jebarani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saravanan Jebarani more than expected).

Fields of papers citing papers by Saravanan Jebarani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saravanan Jebarani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saravanan Jebarani. The network helps show where Saravanan Jebarani may publish in the future.

Co-authorship network of co-authors of Saravanan Jebarani

This figure shows the co-authorship network connecting the top 25 collaborators of Saravanan Jebarani. A scholar is included among the top collaborators of Saravanan Jebarani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saravanan Jebarani. Saravanan Jebarani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Severe insulin‐deficient diabetes is at the opposite end of the neuropathy spectrum to mild aged‐related diabetes 2025 ·Journal of Diabetes Investigation ·Brian C. Callaghan, RanjitMohan Anjana, (unknown), Evan L. Reynolds, Saravanan Jebarani, (unknown), (unknown), Eva L. Feldman, Viswanathan Mohan	1
2	Prevalence of Hepatic Steatosis and Fibrosis in Asian Indian Individuals with Type 2 Diabetes 2025 ·Diabetes Therapy ·(unknown), (unknown), Anandakumar Amutha, (unknown), (unknown), (unknown), P. Routray, (unknown), Saravanan Jebarani, Ulagamathesan Venkatesan, Rosette J. Chakkalakal, S. Shalimar, (unknown), D. Nageshwar Reddy, Anand V. Kulkarni, (unknown), Ranjit Mohan Anjana, (unknown), Viswanathan Mohan	3
3	Lean diabetes is one end of the spectrum of type 2 diabetes and not a separate entity 2025 ·Diabetes Research and Clinical Practice ·Viswanathan Mohan, (unknown), Mohan Deepa, (unknown), Ranjit Unnikrishnan, P. Routray, (unknown), (unknown), (unknown), (unknown), Saravanan Jebarani, Ulagamathesan Venkatesan, (unknown), Ranjit Mohan Anjana	1
4	Development and Validation of DIANA (Diabetes Novel Subgroup Assessment tool): A web-based precision medicine tool to determine type 2 diabetes endotype membership and predict individuals at risk of microvascular disease 2025 ·PLOS Digital Health ·(unknown), (unknown), Subha V. Raman, (unknown), Balaji Bhavadharini, Nico Steckhan, (unknown), Moneeza K. Siddiqui, Saravanan Jebarani, (unknown), Viswanathan Mohan, Ranjit Mohan Anjana	0
5	Prevalence, clinical features and complications of common forms of Maturity Onset Diabetes of the Young (MODY) seen at a tertiary diabetes centre in south India 2023 ·Primary care diabetes ·Ramasamy Aarthy, Kathryn Aston‐Mourney, Anandakumar Amutha, Antonina Mikocka‐Walus, Ranjit Mohan Anjana, Ranjit Unnikrishnan, Saravanan Jebarani, Ulagamathesan Venkatesan, (unknown), Venkatesan Radha, Viswanathan Mohan	4
6	Sex-Based Differences in Clinical Profile and Complications among Individuals with Type 2 Diabetes Seen at a Private Tertiary Diabetes Care Centre in India 2023 ·Healthcare ·Rajendra Pradeepa, (unknown), Ranjit Mohan Anjana, Saravanan Jebarani, Ulagamathesan Venkatesan, (unknown), (unknown), Viswanathan Mohan	5
7	Identification of appropriate biochemical parameters and cut points to detect Maturity Onset Diabetes of Young (MODY) in Asian Indians in a clinic setting 2023 ·Scientific Reports ·Ramasamy Aarthy, Kathryn Aston‐Mourney, Anandakumar Amutha, Antonina Mikocka‐Walus, Ranjit Mohan Anjana, Ranjit Unnikrishnan, Saravanan Jebarani, Ulagamathesan Venkatesan, (unknown), Venkatesan Radha, Viswanathan Mohan	7
8	Development and validation of predictive risk models for sight threatening diabetic retinopathy in patients with type 2 diabetes to be applied as triage tools in resource limited settings 2022 ·EClinicalMedicine ·Manjula D. Nugawela, Sarega Gurudas, A Toby Prevost, Rohini Mathur, John Robson, Thirunavukkarasu Sathish, James Rafferty, Ramachandran Rajalakshmi, Ranjit Mohan Anjana, Saravanan Jebarani, Viswanathan Mohan, David R. Owens, Sobha Sivaprasad	11
9	Tele-Ophthalmology Versus Face-to-Face Retinal Consultation for Assessment of Diabetic Retinopathy in Diabetes Care Centers in India: A Multicenter Cross-Sectional Study 2022 ·Diabetes Technology & Therapeutics ·Ramachandran Rajalakshmi, (unknown), Vijayaraghavan Prathiba, Ranjit Mohan Anjana, Ranjit Unnikrishnan, Ulagamathesan Venkatesan, Saravanan Jebarani, Coimbatore Subramanian Shanthirani, Sobha Sivaprasad, Viswanathan Mohan	10
10	Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell function 2022 ·Diabetologia ·Moneeza K. Siddiqui, Ranjit Mohan Anjana, Adem Y. Dawed, (unknown), Sundararajan Srinivasan, Saravanan Jebarani, (unknown), (unknown), Samira Bell, Abirami Veluchamy, Rajendra Pradeepa, Naveed Sattar, Venkatesan Radha, (unknown), Ewan R. Pearson, Viswanathan Mohan	53
11	Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India 2021 ·Diabetes & Metabolic Syndrome Clinical Research & Reviews ·(unknown), (unknown), (unknown), (unknown), Saravanan Jebarani, Anandakumar Amutha, Mohan Deepa, (unknown), (unknown), Ranjit Unnikrishnan, Ranjit Mohan Anjana, (unknown), Viswanathan Mohan	5
12	Clinical Profile of Long-Term Survivors and Nonsurvivors with Type 1 Diabetes in India 2021 ·Diabetes Technology & Therapeutics ·Viswanathan Mohan, Coimbatore Subramanian Shanthi Rani, Banshi Saboo, Satinath Mukhopadhyay, (unknown), (unknown), Sunil Gupta, Sharad Pendsey, (unknown), (unknown), Anandakumar Amutha, (unknown), (unknown), (unknown), (unknown), Saravanan Jebarani, Nadiminty Ganapathi Sastry, Ulagamathesan Venkatesan, Ranjit Mohan Anjana, Ranjit Unnikrishnan	3
13	Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes 2021 ·Scientific Reports ·Sarega Gurudas, Manjula D. Nugawela, A Toby Prevost, Thirunavukkarasu Sathish, Rohini Mathur, James Rafferty, Kevin Blighe, Ramachandran Rajalakshmi, Anjana Ranjit Mohan, Saravanan Jebarani, Azeem Majeed, (unknown), David R. Owens, John Robson, Sobha Sivaprasad, (unknown)	7
14	Profiles of Intraday Glucose in Type 2 Diabetes and Their Association with Complications: An Analysis of Continuous Glucose Monitoring Data 2021 ·Diabetes Technology & Therapeutics ·Jithin Sam Varghese, Joyce C. Ho, Ranjit Mohan Anjana, Rajendra Pradeepa, Shivani A. Patel, Saravanan Jebarani, (unknown), K.M. Venkat Narayan, Viswanathan Mohan	21
15	Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown 2020 ·Diabetes Technology & Therapeutics ·Ranjit Mohan Anjana, Rajendra Pradeepa, Mohan Deepa, Saravanan Jebarani, Ulagamathesan Venkatesan, (unknown), Muthuswamy Balasubramanyam, Venkatesan Radha, Subramani Poongothai, Vasudevan Sudha, Coimbatore Subramanian Shanthi Rani, Harish Ranjani, Anandakumar Amutha, Nagaraj Manickam, Ranjit Unnikrishnan, Viswanathan Mohan	52
16	Clinical Profile of Elderly Patients (Over 90 Years) with Type 2 Diabetes Seen at a Diabetes Center in South India 2019 ·Diabetes Technology & Therapeutics ·Viswanathan Mohan, Anjana Ranjit Mohan, Ranjit Unnikrishnan, (unknown), (unknown), Saravanan Jebarani, Ulagamathesan Venkatesan, (unknown), (unknown), R. Ashok Kumar, (unknown), Rajendra Pradeepa, (unknown)	8
17	Metabolic profile of normal glucose-tolerant subjects with elevated 1-h plasma glucose values 2016 ·Indian Journal of Endocrinology and Metabolism ·Rajendra Pradeepa, (unknown), Miranda Priya, Saravanan Jebarani, RanjitMohan Anjana, Viswanathan Mohan	5
18	Prevalence and clinical profile of metabolic syndrome among type 1 diabetes mellitus patients in southern India 2015 ·Journal of Diabetes and its Complications ·(unknown), Ranjit Mohan Anjana, Michelle Ngai, Anandakumar Amutha, Rajendra Pradeepa, Saravanan Jebarani, Ranjit Unnikrishnan, Edwin Michael, Viswanathan Mohan	24
19	Association of Neutrophil-Lymphocyte Ratio with Glucose Intolerance: An Indicator of Systemic Inflammation in Patients with Type 2 Diabetes 2014 ·Diabetes Technology & Therapeutics ·(unknown), Bibin Yesodha Subramanian, Coimbatore Subramanian Shanthirani, (unknown), Ranjit Mohan Anjana, Muthuswamy Balasubramanyam, Saravanan Jebarani, Viswanathan Mohan	107
20	Prevalence, incidence and progression of peripheral arterial disease in Asian Indian type 2 diabetic patients 2014 ·Journal of Diabetes and its Complications ·Jayasheel Eshcol, Saravanan Jebarani, Ranjit Mohan Anjana, Viswanathan Mohan, Rajendra Pradeepa	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact